Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives

Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells

(2012) Antonella Naldini et al.   Anti-Cancer Agents in Medicinal Chemistry

Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells

(2011) Sung-Ok Kim et al.   BMB Reports

HDAC inhibitors in parasitic diseases

(2011) Katherine T Andrews et al.   IMMUNOLOGY AND CELL BIOLOGY

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

(2011) Karen M VanderMolen et al.   JOURNAL OF ANTIBIOTICS

Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities

(2011) Yingjie Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oxime Amides as a Novel Zinc Binding Group in Histone Deacetylase Inhibitors: Synthesis, Biological Activity, and Computational Evaluation

(2011) Cinzia B. Botta et al.   JOURNAL OF MEDICINAL CHEMISTRY

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies

(2011) A. Petrella et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

A close look at cancer

(2011) Alison Farrell   NATURE MEDICINE

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

(2011) Nicholas B. La Thangue et al.   Nature Reviews Clinical Oncology

Epigenetics, Nervous System Tumors, and Cancer Stem Cells

(2011) Irfan A. Qureshi et al.   Cancers

Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1

(2010) Cosimo Walter D’Acunto et al.   CANCER LETTERS

Inside HDAC with HDAC inhibitors

(2010) Philippe Bertrand   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

(2010) Paul A Marks   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity

(2010) Luciana Auzzas et al.   JOURNAL OF MEDICINAL CHEMISTRY

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

(2010) Julia M. Wagner et al.   Clinical Epigenetics

N-Hydroxy-(4-oxime)-cinnamide: A versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors

(2009) Giuseppe Giannini et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors

(2009) Takayoshi Suzuki   CHEMICAL & PHARMACEUTICAL BULLETIN

Azetidinones as Zinc-Binding Groups to Design Selective HDAC8 Inhibitors

(2009) Paola Galletti et al.   ChemMedChem

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

New patented histone deacetylase inhibitors

(2009) Haishan Wang et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation

(2009) E Borbone et al.   ONCOGENE

Multiple roles of HDAC inhibition in neurodegenerative conditions

(2009) De-Maw Chuang et al.   TRENDS IN NEUROSCIENCES

Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222

(2008) Simone Di Micco et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of Annexin A1

(2008) Antonello Petrella et al.   EUROPEAN JOURNAL OF CANCER

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment

(2008) Yadong Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6

(2008) Alan P. Kozikowski et al.   JOURNAL OF MEDICINAL CHEMISTRY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY